When was Akero Therapeutics founded?

Akero Therapeutics was founded in 2017 and raised its 1st funding round 1 year after it was founded.

Where is Akero Therapeutics located?

Akero Therapeutics is headquartered in San Francisco, United States. It is registered at South San Francisco, California.

Who is the current CEO of Akero Therapeutics?

Jonathan Young of Akero Therapeutics.

How many employees does Akero Therapeutics have?

As of May 31, 2026, the latest employee count at Akero Therapeutics is 74.

Is Akero Therapeutics a funded company?

Akero Therapeutics is a funded company, having raised a total of $135M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jun 22, 2018.

How much is Akero Therapeutics worth?

The last known valuation of Akero Therapeutics was $***** as of Oct 09, 2025.

When was the latest funding round of Akero Therapeutics?

Akero Therapeutics' latest funding was a $***** Post IPO round on Jun 16, 2022, with participation from 1 investor.

Where does Akero Therapeutics rank among its competitors?

Akero Therapeutics ranks 9th amongst 128 active competitors, of which 43 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Mirum Pharmaceuticals, which secured $68.5M in Jan, 2026.

Who are the top competitors of Akero Therapeutics?

Akero Therapeutics' top competitors include Nimbus Therapeutics, Intercept Pharmaceuticals and Madrigal Pharmaceuticals. Among them, Mirum Pharmaceuticals secured the most recent funding round in January, 2026.

Akero Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Akero Therapeutics is an acquired company based in San Francisco (United States), founded in 2017 by Jonathan Young and Tim Rolph. It operates as a Developer of small molecule therapeutics for metabolic disorders. Akero Therapeutics has raised $135M in funding from investors like Atlas Venture, Apple Tree Partners and Janus Henderson Investors, with last known valuation of $*****. The company has 128 active competitors, including 43 funded and 37 that have exited. Its top competitors include companies like Nimbus Therapeutics, Intercept Pharmaceuticals and Madrigal Pharmaceuticals.

Company Details

Developer of small molecule therapeutics for metabolic disorders. The company's lead product Efruxifermin that acts as an agonist of fibroblast growth factor 21 (FGF21) for the treatment of non-alcoholic steatohepatitis. It also offers products for fibrosis and liver diseases.

Website: akerotx.com
Social
Phone Number: +1 **********
Registered Address: South San Francisco, California

Key Metrics

Founded Year

2017

Location

San Francisco, United States

Stage

Acquired

Total Funding

$135M in 4 rounds

Latest Funding Round

Post IPO, Jun 16, 2022, $*****

Last Known Valuation

$***** as on Oct 09, 2025

Investors

Atlas Venture & 13 more

Ranked

9^th among 128 active competitors

Employee Count

74 as on May 31, 2026

Similar Companies

Nimbus Therapeutics & 81 more

Exit Details

Acquired by New Nordic (Oct 09, 2025)

View Akero Therapeutics' full profile

Akero Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
AKERO THERAPEUTICS, INC. CIN: 815266573 , United States, Active		-	61 (As on Dec 31, 2024)	-

Akero Therapeutics got acquired by New Nordic on Oct 09, 2025 at an acquisition amount of $*****.

Click here to take a look at Akero Therapeutics's acquisition in detail

Akero Therapeutics has raised a total funding of $135M over 4 rounds. Its first funding round was on Jun 22, 2018. Its latest funding round was a Post IPO round on Jun 16, 2022 for $*****. 1 investor participated in its latest round. Akero Therapeutics has 14 institutional investors.

Here is the list of recent funding rounds of Akero Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 16, 2022	2632628	Post IPO	6973509	9498440	1297404	5453307
Jul 10, 2020	2066809	Post IPO	1975643	7818746	8882730	5524462
Dec 12, 2018	6690571	Series B	2057873	2876246	Janus Henderson Investors	LifeSci Venture Partners & 9 more

Access funding benchmarks and valuations. Sign up today!

View details of Akero Therapeutics's funding rounds and investors

The founders of Akero Therapeutics are Jonathan Young and Tim Rolph.

Here are the details of Akero Therapeutics' key team members:

Jonathan Young: CEO of Akero Therapeutics.
Contact Info: 1 email address
Tim Rolph: Co-Founder of Akero Therapeutics.
Contact Info: 1 email address

View details of Akero Therapeutics's Founder profiles and Board Members

Akero Therapeutics' employee count trend

Akero Therapeutics has 74 employees as of May 26. Here is Akero Therapeutics's employee count trend over the years:

Employee count trend for Akero Therapeutics

Uncover Akero Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Akero Therapeutics include Nimbus Therapeutics, Intercept Pharmaceuticals and Madrigal Pharmaceuticals. Here is the list of Top 10 competitors of Akero Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Pfizer Venture Investments ... & 20 others	68/100
2nd	Intercept Pharmaceuticals 2002, New York City (United States), Acquired	Developer of therapeutics to treat progressive non-viral liver diseases	$121M	Orbimed, JAFCO Group & 7 others	67/100
3rd	Madrigal Pharmaceuticals 2011, Conshohocken (United States), Acquired	Develops small molecule drugs for the treatment of cardiovascular and metabolic diseases and non-alcoholic steatohepatitis	$38.4M	The Pritzker Organization, Bay City Capital ... & 3 others	66/100
4th	Mammoth 2017, Brisbane (United States), Series D	Provider of molecular diagnostics platform by using CRISPR technology	$271M	Redmile Group, 8VC & 34 others	65/100
5th	Mirum Pharmaceuticals 2018, Menlo Park (United States), Public	Developer of small molecule based therapeutics to treat rare diseases	$120M	New Enterprise Associates, Chiesi Ventures ... & 9 others	64/100
6th	Drug Farm 2015, Shanghai (China), Series C	Developer of a novel treatment for metabolic diseases	$83M	Zhejiang Private Enterprise United Investment, South China Venture Capital ... & 7 others	63/100
7th	Ochre Bio 2019, Oxford (United Kingdom), Series A	Developer of ribonucleic acid therapies for treating chronic liver diseases	$39.7M	Khosla Ventures, Y Combinator & 21 others	62/100
8th	Enyo Pharma 2014, Lyon (France), Series C	Developer of therapeutics for diseases with impaired kidney function	$120M	Orbimed, Sofinnova Partners & 9 others	62/100
9th	Akero Therapeutics 2017, San Francisco (United States), Acquired	Developer of small molecule therapeutics for metabolic disorders	$135M	BVF Partners, Pfizer & 12 others	61/100
10th	Altimmune 1997, Gaithersburg (United States), Acquired	Developer of vaccines for infectious disease including influenza, hepatitis B and solid tumors	$58M	Military Health, HHS & 15 others	60/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Akero Therapeutics's competitors? Click here to see the top ones

Akero Therapeutics has made no investments or acquisitions yet.

Media has covered Akero Therapeutics for a total of 27 events in the last 1 year, 10 of them have been about company updates and 1 about people movement.